Please Wait.....
Report
Image-Guided Radiation Therapy Market By Product (4D RT, LINAC, MRI-guided Radiotherapy, Portal Imaging, CT Scanning), By Procedure (IMRT (intensity modulation radiation therapy), Stereotactic Therapy, Particle Therapy, Others) By End User (Hospitals, Independent Radiotherapy Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 260 Pages I Allied Market Research
Image-guided Radiation Therapy Market
The image-guided radiation therapy market was valued at $1.9 billion in 2023 and is projected to reach $3.3 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.
Image-guided radiation therapy is a frequent imaging process used in the treatment of cancer. The therapy involves several imaging techniques such as MRI, PET, and CT scans, which allow for precise targeting of radiation for killing the cancer cells. The precise targeting is performed using the high-quality images generated by imaging technologies. This approach elevates the accuracy of treatment, improves therapy outcomes, and reduces radiation-related complications, making image-guided radiation therapy a necessary procedure in modern oncology practice.
Increase in prevalence of diverse forms of cancers and rise in demand for targeted cancer treatment are the major drivers of the image-guided radiation therapy market. In addition, the deployment of real-time imaging during ongoing treatment sessions has boosted the efficacy of treatment, thereby boosting the demand for image-guided radiation therapy. Surface-guided radiation therapy has recently witnessed widespread adoption in several oncology facilities due to its cutting-edge attributes such as intra-fraction motion monitoring and respiratory gating.
However, the cost associated with procuring instruments related to image-guided radiation therapy, along with the high costs of treatment for the patients, is a major restraint for the market. On the contrary, enhancements in technology are diversifying the prospects of the therapy and refining the healing process. Assimilation of AI and ML is enabling the delivery of personalized cancer treatment according to the vitals and requirements of the patient. For instance, in the case of a patient suffering from glioblastoma, an AI-based dose optimization software was used to tailor the radiation therapy. This included the delivery of optimal dose of radiation, resulting in maximum tumor control while guarding the pivotal parts of the brain such as brainstem and optic nerves.
Segment Review
The image-guided radiation therapy market is segmented into product, procedure, end user, and region. On the basis of product, the market is divided into 4D RT, LINAC, MRI-guided radiotherapy, portal imaging, and CT scanning. By procedure, it is classified into IMRT (intensity modulation radiation therapy), stereotactic therapy, particle therapy, and others. Depending on end user, it is categorized into hospitals, independent radiotherapy centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product, the LINAC segment dominates the market.
By procedure, the IMRT (intensity modulation radiation therapy) segment is the leader in the market.
Region wise, North America is projected to be the highest revenue generator by 2033.
Competition Analysis
The major players operating in the global image-guided radiation therapy market include Varian Medical Systems, Inc., Elekta AB, Accuray Incorporated, ViewRay, Inc., Siemens Healthineers AG, Hitachi, Ltd, Brainlab AG, MEVION MEDICAL SYSTEMS, INC., C-Rad AB, Sumitomo Heavy Industries, Ltd., and Philips Healthcare. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
Key Market Segments
By Product
- 4D RT
- LINAC
- MRI-guided Radiotherapy
- Portal Imaging
- CT Scanning
By Procedure
- IMRT (intensity modulation radiation therapy)
- Stereotactic Therapy
- Particle Therapy
- Others
By End User
- Hospitals
- Independent Radiotherapy Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Varian Medical Systems, Inc.
- Elekta AB, Accuray Incorporated
- ViewRay, Inc.
- Siemens Healthineers AG
- Hitachi, Ltd
- Brainlab AG
- MEVION MEDICAL SYSTEMS, INC.
- C-Rad AB
- Sumitomo Heavy Industries, Ltd.
- Philips Healthcare
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: LIPID NANOPARTICLES MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Solid Lipid Nanoparticles
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Nanostructured Lipid Carriers
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Others
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: LIPID NANOPARTICLES MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Therapeutics
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Research
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: LIPID NANOPARTICLES MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Pharmaceutical And Biotechnology Companies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Academic And Research Institutes
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Others
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: LIPID NANOPARTICLES MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Type
7.2.3. Market Size and Forecast, By Application
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Lipid Nanoparticles Market
7.2.6.1. Market Size and Forecast, By Type
7.2.6.2. Market Size and Forecast, By Application
7.2.6.3. Market Size and Forecast, By End User
7.2.7. Canada Lipid Nanoparticles Market
7.2.7.1. Market Size and Forecast, By Type
7.2.7.2. Market Size and Forecast, By Application
7.2.7.3. Market Size and Forecast, By End User
7.2.8. Mexico Lipid Nanoparticles Market
7.2.8.1. Market Size and Forecast, By Type
7.2.8.2. Market Size and Forecast, By Application
7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Type
7.3.3. Market Size and Forecast, By Application
7.3.4. Market Size and Forecast, By End User
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Lipid Nanoparticles Market
7.3.6.1. Market Size and Forecast, By Type
7.3.6.2. Market Size and Forecast, By Application
7.3.6.3. Market Size and Forecast, By End User
7.3.7. France Lipid Nanoparticles Market
7.3.7.1. Market Size and Forecast, By Type
7.3.7.2. Market Size and Forecast, By Application
7.3.7.3. Market Size and Forecast, By End User
7.3.8. UK Lipid Nanoparticles Market
7.3.8.1. Market Size and Forecast, By Type
7.3.8.2. Market Size and Forecast, By Application
7.3.8.3. Market Size and Forecast, By End User
7.3.9. Italy Lipid Nanoparticles Market
7.3.9.1. Market Size and Forecast, By Type
7.3.9.2. Market Size and Forecast, By Application
7.3.9.3. Market Size and Forecast, By End User
7.3.10. Spain Lipid Nanoparticles Market
7.3.10.1. Market Size and Forecast, By Type
7.3.10.2. Market Size and Forecast, By Application
7.3.10.3. Market Size and Forecast, By End User
7.3.11. Rest of Europe Lipid Nanoparticles Market
7.3.11.1. Market Size and Forecast, By Type
7.3.11.2. Market Size and Forecast, By Application
7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Type
7.4.3. Market Size and Forecast, By Application
7.4.4. Market Size and Forecast, By End User
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Lipid Nanoparticles Market
7.4.6.1. Market Size and Forecast, By Type
7.4.6.2. Market Size and Forecast, By Application
7.4.6.3. Market Size and Forecast, By End User
7.4.7. China Lipid Nanoparticles Market
7.4.7.1. Market Size and Forecast, By Type
7.4.7.2. Market Size and Forecast, By Application
7.4.7.3. Market Size and Forecast, By End User
7.4.8. India Lipid Nanoparticles Market
7.4.8.1. Market Size and Forecast, By Type
7.4.8.2. Market Size and Forecast, By Application
7.4.8.3. Market Size and Forecast, By End User
7.4.9. Australia Lipid Nanoparticles Market
7.4.9.1. Market Size and Forecast, By Type
7.4.9.2. Market Size and Forecast, By Application
7.4.9.3. Market Size and Forecast, By End User
7.4.10. South Korea Lipid Nanoparticles Market
7.4.10.1. Market Size and Forecast, By Type
7.4.10.2. Market Size and Forecast, By Application
7.4.10.3. Market Size and Forecast, By End User
7.4.11. Rest of Asia-Pacific Lipid Nanoparticles Market
7.4.11.1. Market Size and Forecast, By Type
7.4.11.2. Market Size and Forecast, By Application
7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Type
7.5.3. Market Size and Forecast, By Application
7.5.4. Market Size and Forecast, By End User
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Lipid Nanoparticles Market
7.5.6.1. Market Size and Forecast, By Type
7.5.6.2. Market Size and Forecast, By Application
7.5.6.3. Market Size and Forecast, By End User
7.5.7. Saudi Arabia Lipid Nanoparticles Market
7.5.7.1. Market Size and Forecast, By Type
7.5.7.2. Market Size and Forecast, By Application
7.5.7.3. Market Size and Forecast, By End User
7.5.8. South Africa Lipid Nanoparticles Market
7.5.8.1. Market Size and Forecast, By Type
7.5.8.2. Market Size and Forecast, By Application
7.5.8.3. Market Size and Forecast, By End User
7.5.9. Rest of LAMEA Lipid Nanoparticles Market
7.5.9.1. Market Size and Forecast, By Type
7.5.9.2. Market Size and Forecast, By Application
7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. ABP Biosciences, LLC.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Merck KGaA
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Cytiva
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. CD Bioparticles
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. CordenPharma
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Precigenome LLC.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Beam Therapeutics
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Acuitas Therapeutics.
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Helix Biotech, Inc.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Genevant Sciences Corporation
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 2. IMAGE-GUIDED RADIATION THERAPY MARKET FOR 4D RT, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. IMAGE-GUIDED RADIATION THERAPY MARKET FOR LINAC, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. IMAGE-GUIDED RADIATION THERAPY MARKET FOR MRI-GUIDED RADIOTHERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. IMAGE-GUIDED RADIATION THERAPY MARKET FOR PORTAL IMAGING, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. IMAGE-GUIDED RADIATION THERAPY MARKET FOR CT SCANNING, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 8. IMAGE-GUIDED RADIATION THERAPY MARKET FOR IMRT (INTENSITY MODULATION RADIATION THERAPY), BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. IMAGE-GUIDED RADIATION THERAPY MARKET FOR STEREOTACTIC THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. IMAGE-GUIDED RADIATION THERAPY MARKET FOR PARTICLE THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. IMAGE-GUIDED RADIATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 13. IMAGE-GUIDED RADIATION THERAPY MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. IMAGE-GUIDED RADIATION THERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. IMAGE-GUIDED RADIATION THERAPY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. IMAGE-GUIDED RADIATION THERAPY MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA IMAGE-GUIDED RADIATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 18. NORTH AMERICA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 19. NORTH AMERICA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 20. NORTH AMERICA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. U.S. IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 22. U.S. IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 23. U.S. IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 24. CANADA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 25. CANADA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 26. CANADA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. MEXICO IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 28. MEXICO IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 29. MEXICO IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE IMAGE-GUIDED RADIATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 31. EUROPE IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 32. EUROPE IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 33. EUROPE IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 34. FRANCE IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 35. FRANCE IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 36. FRANCE IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 37. GERMANY IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 38. GERMANY IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 39. GERMANY IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. ITALY IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 41. ITALY IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 42. ITALY IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 43. SPAIN IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 44. SPAIN IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 45. SPAIN IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. UK IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 47. UK IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 48. UK IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 49. REST OF EUROPE IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 50. REST OF EUROPE IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 51. REST OF EUROPE IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC IMAGE-GUIDED RADIATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 53. ASIA-PACIFIC IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 54. ASIA-PACIFIC IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 55. ASIA-PACIFIC IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 56. CHINA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 57. CHINA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 58. CHINA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. JAPAN IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 60. JAPAN IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 61. JAPAN IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 62. INDIA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 63. INDIA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 64. INDIA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 65. SOUTH KOREA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 66. SOUTH KOREA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 67. SOUTH KOREA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 68. AUSTRALIA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 69. AUSTRALIA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 70. AUSTRALIA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 71. REST OF ASIA-PACIFIC IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 72. REST OF ASIA-PACIFIC IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 73. REST OF ASIA-PACIFIC IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA IMAGE-GUIDED RADIATION THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 75. LAMEA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 76. LAMEA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 77. LAMEA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 78. BRAZIL IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 79. BRAZIL IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 80. BRAZIL IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 81. SOUTH AFRICA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 82. SOUTH AFRICA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 83. SOUTH AFRICA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 84. SAUDI ARABIA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 85. SAUDI ARABIA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 86. SAUDI ARABIA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 87. REST OF LAMEA IMAGE-GUIDED RADIATION THERAPY, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 88. REST OF LAMEA IMAGE-GUIDED RADIATION THERAPY, BY PROCEDURE, 2024 - 2033 ($BILLION)
TABLE 89. REST OF LAMEA IMAGE-GUIDED RADIATION THERAPY, BY END USER, 2024 - 2033 ($BILLION)
TABLE 90. VARIAN MEDICAL SYSTEMS, INC.: KEY EXECUTIVES
TABLE 91. VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT
TABLE 92. VARIAN MEDICAL SYSTEMS, INC.: OPERATING SEGMENTS
TABLE 93. VARIAN MEDICAL SYSTEMS, INC.: PRODUCT PORTFOLIO
TABLE 94. VARIAN MEDICAL SYSTEMS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95. ELEKTA AB, ACCURAY INCORPORATED: KEY EXECUTIVES
TABLE 96. ELEKTA AB, ACCURAY INCORPORATED: COMPANY SNAPSHOT
TABLE 97. ELEKTA AB, ACCURAY INCORPORATED: OPERATING SEGMENTS
TABLE 98. ELEKTA AB, ACCURAY INCORPORATED: PRODUCT PORTFOLIO
TABLE 99. ELEKTA AB, ACCURAY INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100. VIEWRAY, INC.: KEY EXECUTIVES
TABLE 101. VIEWRAY, INC.: COMPANY SNAPSHOT
TABLE 102. VIEWRAY, INC.: OPERATING SEGMENTS
TABLE 103. VIEWRAY, INC.: PRODUCT PORTFOLIO
TABLE 104. VIEWRAY, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
TABLE 106. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 107. SIEMENS HEALTHINEERS AG: OPERATING SEGMENTS
TABLE 108. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 109. SIEMENS HEALTHINEERS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110. HITACHI, LTD: KEY EXECUTIVES
TABLE 111. HITACHI, LTD: COMPANY SNAPSHOT
TABLE 112. HITACHI, LTD: OPERATING SEGMENTS
TABLE 113. HITACHI, LTD: PRODUCT PORTFOLIO
TABLE 114. HITACHI, LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. BRAINLAB AG: KEY EXECUTIVES
TABLE 116. BRAINLAB AG: COMPANY SNAPSHOT
TABLE 117. BRAINLAB AG: OPERATING SEGMENTS
TABLE 118. BRAINLAB AG: PRODUCT PORTFOLIO
TABLE 119. BRAINLAB AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. MEVION MEDICAL SYSTEMS, INC.: KEY EXECUTIVES
TABLE 121. MEVION MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT
TABLE 122. MEVION MEDICAL SYSTEMS, INC.: OPERATING SEGMENTS
TABLE 123. MEVION MEDICAL SYSTEMS, INC.: PRODUCT PORTFOLIO
TABLE 124. MEVION MEDICAL SYSTEMS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. C-RAD AB: KEY EXECUTIVES
TABLE 126. C-RAD AB: COMPANY SNAPSHOT
TABLE 127. C-RAD AB: OPERATING SEGMENTS
TABLE 128. C-RAD AB: PRODUCT PORTFOLIO
TABLE 129. C-RAD AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. SUMITOMO HEAVY INDUSTRIES, LTD.: KEY EXECUTIVES
TABLE 131. SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY SNAPSHOT
TABLE 132. SUMITOMO HEAVY INDUSTRIES, LTD.: OPERATING SEGMENTS
TABLE 133. SUMITOMO HEAVY INDUSTRIES, LTD.: PRODUCT PORTFOLIO
TABLE 134. SUMITOMO HEAVY INDUSTRIES, LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 135. PHILIPS HEALTHCARE: KEY EXECUTIVES
TABLE 136. PHILIPS HEALTHCARE: COMPANY SNAPSHOT
TABLE 137. PHILIPS HEALTHCARE: OPERATING SEGMENTS
TABLE 138. PHILIPS HEALTHCARE: PRODUCT PORTFOLIO
TABLE 139. PHILIPS HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET SEGMENTATION
FIGURE 2. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET
FIGURE 3. SEGMENTATION IMAGE-GUIDED RADIATION THERAPY MARKET
FIGURE 4. TOP INVESTMENT POCKET IN IMAGE-GUIDED RADIATION THERAPY MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMAGE-GUIDED RADIATION THERAPY MARKET
FIGURE 11. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET SEGMENTATION, BY PRODUCT
FIGURE 12. IMAGE-GUIDED RADIATION THERAPY MARKET FOR 4D RT, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. IMAGE-GUIDED RADIATION THERAPY MARKET FOR LINAC, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. IMAGE-GUIDED RADIATION THERAPY MARKET FOR MRI-GUIDED RADIOTHERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. IMAGE-GUIDED RADIATION THERAPY MARKET FOR PORTAL IMAGING, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. IMAGE-GUIDED RADIATION THERAPY MARKET FOR CT SCANNING, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET SEGMENTATION, BY PROCEDURE
FIGURE 18. IMAGE-GUIDED RADIATION THERAPY MARKET FOR IMRT (INTENSITY MODULATION RADIATION THERAPY), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. IMAGE-GUIDED RADIATION THERAPY MARKET FOR STEREOTACTIC THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. IMAGE-GUIDED RADIATION THERAPY MARKET FOR PARTICLE THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. IMAGE-GUIDED RADIATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. GLOBAL IMAGE-GUIDED RADIATION THERAPY MARKET SEGMENTATION, BY END USER
FIGURE 23. IMAGE-GUIDED RADIATION THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. IMAGE-GUIDED RADIATION THERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. IMAGE-GUIDED RADIATION THERAPY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 30. COMPETITIVE DASHBOARD
FIGURE 31. COMPETITIVE HEATMAP: IMAGE-GUIDED RADIATION THERAPY MARKET
FIGURE 32. TOP PLAYER POSITIONING, 2023
FIGURE 33. VARIAN MEDICAL SYSTEMS, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 34. VARIAN MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. VARIAN MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. ELEKTA AB, ACCURAY INCORPORATED: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. ELEKTA AB, ACCURAY INCORPORATED: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. ELEKTA AB, ACCURAY INCORPORATED: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. VIEWRAY, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. VIEWRAY, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. VIEWRAY, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. SIEMENS HEALTHINEERS AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. SIEMENS HEALTHINEERS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. SIEMENS HEALTHINEERS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. HITACHI, LTD: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. HITACHI, LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. HITACHI, LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. BRAINLAB AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. BRAINLAB AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. BRAINLAB AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. MEVION MEDICAL SYSTEMS, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. MEVION MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. MEVION MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. C-RAD AB: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. C-RAD AB: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. C-RAD AB: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. SUMITOMO HEAVY INDUSTRIES, LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. SUMITOMO HEAVY INDUSTRIES, LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. SUMITOMO HEAVY INDUSTRIES, LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 60. PHILIPS HEALTHCARE: NET SALES, 2021-2023 ($BILLION)
FIGURE 61. PHILIPS HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 62. PHILIPS HEALTHCARE: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security